Lawsuits are threatening to disrupt the supply of baby formula critical for premature infants as litigation against manufacturers surges.
At a Glance
- A landmark $495 million verdict against Abbott Laboratories has sparked a flood of new lawsuits.
- There are currently 744 active lawsuits in federal court, with more in state courts.
- Healthcare providers are now being targeted in these lawsuits for recommending cow’s milk-based formulas.
- Potential formula shortages could arise if manufacturers withdraw from the market under legal pressure.
The Legal Battle over Baby Formula
The legal storm surrounding baby formula manufacturers has intensified since a jury awarded $495 million to the family of an infant affected by necrotizing enterocolitis (NEC). This condition, which predominantly impacts premature infants, has been linked to cow’s milk-based formulas like Similac and Enfamil. Families allege these manufacturers failed to adequately warn consumers about the risks. The August 2024 verdict against Abbott Laboratories has opened the floodgates, leading to a surge of lawsuits and expanding claims to include healthcare providers who recommended these formulas.
The heart of these lawsuits is the assertion that manufacturers knew about the increased risks of NEC from cow’s milk-based formulas but continued marketing them as safe alternatives to breast milk. This has been a decades-long issue, with some cases dating back over 20 years, which makes proving these allegations challenging due to the difficulty in obtaining historical medical records. Nonetheless, the current wave of lawsuits is unprecedented in scale and impact, potentially reshaping the entire infant formula industry.
The Stakeholders and Their Stakes
Major manufacturers like Abbott Laboratories and Reckitt Benckiser, the producer of Enfamil, are at the center of this legal maelstrom. For these companies, the stakes are enormous — not just in terms of financial liability but also in reputational costs and market share. Healthcare providers, including neonatologists and hospitals, who are now being sued for recommending these formulas, play a crucial role as gatekeepers. They are facing intense scrutiny over their advice to parents of preterm infants.
The plaintiff families, primarily parents seeking compensation and accountability, wield limited power individually. However, through collective legal action and the consolidation of cases into a multidistrict litigation (MDL), they have gained significant leverage. Federal courts, particularly the MDL 3026 overseen by Judge Pallmeyer, are central to these proceedings, with hundreds of millions already awarded to plaintiffs in various verdicts. Meanwhile, lawmakers are voicing concerns over potential formula shortages should manufacturers decide to exit the preterm formula market.
Current Developments and Implications
As of July 2025, the legal landscape is dynamic and unpredictable. Abbott Laboratories recently won summary judgment in the first federal bellwether trial, yet the decision’s limited scope means the broader litigation continues. Additionally, a retrial was ordered in a case due to defense misconduct, highlighting the volatility of these proceedings. The ongoing litigation increasingly targets healthcare providers, challenging their recommendations of cow’s milk-based formulas for preterm infants.
Despite these developments, the central debate remains unresolved — whether the risk of NEC is primarily due to cow’s milk-based formulas or the absence of human milk. The defendants argue the latter, citing NIH research. However, the litigation persists, with more bellwether trials and appeals on the horizon. The stakes are high, with potential industry-wide changes in labeling, marketing, and formulation practices. The feared withdrawal of major manufacturers from this niche market could lead to shortages, further complicating the situation for affected families and healthcare providers.
Looking Ahead: The Potential Impact
The short-term implications of these lawsuits are already evident. Manufacturers are confronted with immense financial liabilities and damage to their reputations. Healthcare providers may alter their nutritional recommendations, with increased reliance on donor breast milk or alternative products. For the parents and families of affected infants, compensation might be forthcoming, but it does little to ease the emotional and logistical burdens they face.
Long-term, the ripple effects could reshape the infant formula industry. Regulatory scrutiny might increase, leading to new guidelines for formula safety and hospital feeding protocols. Economic impacts are significant, with the potential for increased costs for hospitals and families if alternatives are pricier or less accessible. Socially, public awareness of infant nutrition risks is heightened, potentially eroding trust in established formula brands. Politically, these issues could spark legislative action to ensure the safety and accessibility of nutrition for vulnerable infants.
